| Patent Number |
Title Of Patent |
Date Issued |
| D325339 |
Combined collapsible tube and cap |
April 14, 1992 |
|
| D324997 |
Container |
March 31, 1992 |
|
| D323292 |
Container |
January 21, 1992 |
|
| D321759 |
Syringe |
November 19, 1991 |
|
| D317563 |
Bag |
June 18, 1991 |
|
| 6964865 |
Host cells comprising Streptomyces clavuligerus chromosomal DNA fragments encoding enzymes for . |
November 15, 2005 |
| DNA sequences obtained from S. clavuligerus ATCC 27064, recombinant vectors incorporating such sequences and hosts transformed with such vectors are disclosed.The DNA comprises one or more genes coding for one or more enzymes involved in the biosynthesis of penicillin and cephalosporin . |
| 6709859 |
Chromosomal DNA Fragments Encoding Enzymes for Encoding B-Lactam Biosynthesis Enzymes, and Vecto |
March 23, 2004 |
| DNA sequences obtained from S. clavuligerus ATCC 27064, recombinant vectors incorporating such sequences and hosts transformed with such vectors are disclosed.The DNA comprises one or more genes coding for one or more enzymes involved in the biosynthesis of penicillin and cephalosporin . |
| 6686475 |
Compounds |
February 3, 2004 |
| Compounds of formula (I): ##STR1##or a tautomeric form thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, wherein: A.sup.1 represents a substituted or unsubstituted aromatic heterocyclyl group; R.sup.1 represents a hydrocarbon |
| 6531600 |
Treatment and compounds |
March 11, 2003 |
| A method for the treatment of cerebrovascular disorders and/or disorders associated with cerebral senility and/or other disorders which method comprises the administration of an effective, non-toxic amount of a compound of formula (I): ##STR1##or if appropriate a pharmaceutically acc |
| 6284736 |
Amphotericin derivatives |
September 4, 2001 |
| A compound of formula (I), or a pharmaceutically acceptable salt thereof: ##STR1##wherein R.sub.1 is a carboxylic acid group, a derivative thereof, a ketone residue, an aldehyde function or optionally substituted methyl; R.sub.2 is hydroxy, C.sub.1-8 alkoxy or a fluorine atom; and R.sub. |
| 6180791 |
Synthesis of 8-substituted xanthines |
January 30, 2001 |
| A method for the treatment of cerebrovascular disorders and/or disorders associated with cerebral senility and/or other disorders which method comprises the administration of an effective, non-toxic amount of a compound of formula (I): ##STR1##or if appropriate a pharmaceutically acc |
| 6077536 |
Pharmaceutical formulation |
June 20, 2000 |
| A pharmaceutical formulation comprising an amoxycillin hydrate and an effervescent couple, for example citric acid plus sodium bicarbonate or sodium glycine carbonate, or tartaric acid or malic acid plus sodium carbonate. Potassium equivalents of these sodium salts may be used. The f |
| 6066468 |
Chromosomal DNA fragments encoding enzymes for encoding .beta.-lactam biosynthetic enzymes, and |
May 23, 2000 |
| DNA sequences obtained from S. clavuligerus ATCC 27064, recombinant vectors incorporating such sequences and hosts transformed with such vectors are disclosed. The DNA comprises one or more genes coding for one or more enzymes involved in the biosynthesis of penicillin and cephalosporin |
| 6037156 |
DNA molecules and vectors encoding clavulanic acid biosynthesis enzymes |
March 14, 2000 |
| DNA sequences obtained from S. clavuligerus, recombinant vectors incorporating such sequences and hosts transformed with such vectors are disclosed. The DNA comprises one or more genes encoding one or more enzymes involved in the biosynthesis of clavulanic acid and may be used to imp |
| 5981545 |
N-linked azabicyclic heterocycles useful for treating dementia |
November 9, 1999 |
| A compound of formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## in which one of X and Y represents hydrogen and the other represents Z, where Z is a group ##STR2## in which Q represents a 3-membered divalent residue completing a 5-membered aromatic ring and |
| 5792790 |
Method for improving weight gain and feed utilization in livestock |
August 11, 1998 |
| Crystalline calcium pseudomonate or a hydrate thereof, in particular the dihydrate.Processes for the preparation of these salts and their use in human and veterinary medicine and as a growth promoter in animals are described. |
| 5759831 |
DNA molecules and vectors regarding clavulanic acid biosynthesis enzymes |
June 2, 1998 |
| DNA sequences obtained from S. clavuligerus, recombinant vectors incorporating such sequences and hosts transformed with such vectors are disclosed. The DNA comprises one or more genes encoding one or more enzymes involved in the biosynthesis of clavulanic acid and may be used to imp |
| 5756525 |
Compounds for treating eating disorders |
May 26, 1998 |
| A method is provided for the treatment and/or prophylaxis of cardiovascular diseases or eating disorders in a human or non-human mammal, which comprises administering to a human or non-human mammal in need thereof, an effective, non-toxic amount of a compound of formula (I): ##STR1## |
| 5750684 |
Process for the preparatin of .beta.-lactam compounds |
May 12, 1998 |
| The present invention provides a process for the substitution of an acylamino .beta.-lactam compound at the carbon atom carrying the acylamino group, which process comprises reacting the .beta.-lactam compound with an halogenating agent and a nucleophilic reagent; characterized in that t |
| 5684153 |
Process for the preparation of purine derivatives |
November 4, 1997 |
| The present invention provides a process for the synthesis of penciclovir and famciclovir by 9-substituting the compound 2-amino-6-chloropurine (ACP) with 2-acetoxymethyl-4-(leaving group)-but-1-yl acetate, followed by displacement of the 6-chloro moiety with a hydroxy moiety (i.e. to fo |
| 5679789 |
Pharmaceutical compositions comprising potassium clavulanate and methods of using them |
October 21, 1997 |
| Potassium clavulanate exists in a novel crystalline habit, namely in the form of rosettes, having improved processing properties. The novel form may, for example, be obtained by crystallization or recrystallization using inverse precipitation, preferably at 8.degree.-15.degree. C. |
| 5674869 |
Pharmaceutical treatment |
October 7, 1997 |
| Use of a guanine derivative or a prodrug thereof in the treatment of viral infections. |
| 5670170 |
Pharamaceutical formulation |
September 23, 1997 |
| A pharmaceutical formulation comprises a medicament and an effervescent couple, plus optionally other excipients. Preferred medicaments are antibiotics, together with a citric acid--sodium bicarbonate couple. The formulation is provided for make up with water into an antibiotic suspe |
| 5646169 |
Compounds for treating eating disorders in which blood glucose levels are raised |
July 8, 1997 |
| A method is provided for the treatment and/or prophylaxis of eating disorders in a human or non-human mammal, which comprises administering to a human or non-human mammal in need thereof, an effective, non-toxic amount of a compound of formula (I): ##STR1## or a tautomeric form t |
| 5554610 |
Inhalational treatment of pulmonary hypertension and related conditions |
September 10, 1996 |
| A method for the treatment and/or prophylaxis of disorders associated with pulmonary hypertension and/or disorders associated with right heart failure, in mammals, such as humans, which method comprises administering to the mammal in need of such treatment and/or prophylaxis an effective |
| 5541194 |
Certain 1-azabicyclo[2.2.1]heptanes and 1-azabicyclo[2.2.2]octanes |
July 30, 1996 |
| Novel compounds of formula (I), processes for their preparation, and their use as pharmaceutical agents are described: ##STR1## in which p represents an integer of 2 to 4; r represents an integer of 1 or 2; s represents 0 or 1; and X represents a group ##STR2## in which A.sub |
| 5470859 |
Azabicyclic compounds with muscarinic activity useful for treating dementia |
November 28, 1995 |
| A pharmaceutical composition useful to treating dementia which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## in which p is 1 and either m is 0 and n is 2 or 3 or m is 1 and n is 2, or p is 2, m is 0 and n is 2, and Z is a heterocyclic gro |
| 5436266 |
Compounds |
July 25, 1995 |
| Crystalline calcium pseudomonate or a hydrate thereof, in particular the dihydrate. Processes for the preparation of these salts and their use in human and veterinary medicine and as a growth promoter in animals are described. |
| 5371092 |
Use of paroxetine for the treatment of senile dementia, bulimia, migraine or anorexia |
December 6, 1994 |
| The method of using paroxetine or a pharmaceutically acceptable salt thereof for the treatment of senile dementia. |
| 5356886 |
Antiviral phosphono-alken derivatives of purines |
October 18, 1994 |
| The present invention provides antiviral compounds of Formula (I), and pharmaceutically acceptable salts thereof: ##STR1## wherein X is --CH.sub.2 O or --CH.sub.2 ;R.sub.1 is hydroxy or amino;R.sub.2 is hydrogen or amino;R.sub.3 is hydrogen, hydroxymethyl or acyloxymethyl, wherein the ac |
| 5310750 |
Heterocyclic compounds useful as .alpha..sub.2 -adrenoceptor antagonists |
May 10, 1994 |
| A compound of formula (I): ##STR1## or a pharmaceutically acceptable salt thereof, wherein: R.sup.1 and R.sup.2 may each represent hydrogen or alkyl providing that at least one of R.sup.1 or R.sup.2 represents alkyl;R.sup.3 and R.sup.4 each represent hydrogen or R.sup.3 and R.sup.4 t |
| 5278170 |
Azabicylo oxime compounds |
January 11, 1994 |
| A compound of formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## wherein R.sup.1 represents ##STR2## in which each of p and q independently represents an integer of 2 to 4, r represents an integer of 2 to 4, s represents 1 or 2 and t represents 0 or 1;R.sub. |
| 5264436 |
Heterocyclic compounds which have useful pharmaceutical utility |
November 23, 1993 |
| A compound of formula (I): ##STR1## or a pharmaceutically acceptable salt, ester or amide thereof, or a pharmaceutically acceptable solvate thereof, wherein:Z represents a residue of a substituted or unsubstituted aryl group,A.sub.1 represents a substituted or unsubstituted methylene gro |
| 5260445 |
2,4-thiazolidinediones |
November 9, 1993 |
| Compounds of formula (I): ##STR1## or a tautomeric form thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, wherein:A.sup.1 represents a substituted or unsubstituted aromatic heterocyclyl group;R.sup.1 represents a hydrogen atom, |
| 5252575 |
Antiviral purine derivatives with improved gastrointestinal absorption |
October 12, 1993 |
| Compounds of formula (I) and pharmaceutically acceptable salts thereof: ##STR1## wherein R.sub.1 is hydrogen or hydroxy; andR.sub.2 is C.sub.1-6 alkyl;which are pro-drugs for 9-(3-hydroxyprop-1-oxy)guanine having antiviral activity, a process for their preparation and their use as ph |
| 5247085 |
Antiviral purine compounds |
September 21, 1993 |
| Compounds of formula (I), and pharmaceutically acceptable salts thereof ##STR1## wherein R.sub.1 is hydroxy, amino, chloro or OR.sub.7 whereinR.sub.7 is C.sub.1-6 alkyl, phenyl or phenyl C.sub.1-2 alkyl either of which phenyl moieties may be substituted by one or two substituents sel |
| 5232925 |
Compounds |
August 3, 1993 |
| Compounds of formula (I): ##STR1## or a tautomeric form thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceuticallyacceptable solvate thereof, wherein:A.sup.1 represents a substituted or unsubstituted aromatic heterocyclyl group;R.sup.1 represents a hydrogen atom, a |
| 5220024 |
Process for the preparation of purine derivatives as antiviral agents |
June 15, 1993 |
| A process for the preparation of a compound of formula (A): ##STR1## wherein X is hydrogen, hydroxy, chloro, C.sub.1-6 alkoxy or phenyl C.sub.1-6 alkoxy and R.sub.a and R.sub.b are hydrogen, including acyl and phosphate derivatives thereof; which process comprises:i) the preparation |
| 5217975 |
Azabicyclic compounds for treating dementia |
June 8, 1993 |
| A compound of formula (I) useful for treating dementia or a pharmaceutically acceptable salt thereof: ##STR1## in which one of X and Y represents hydrogen and the other represents Z, where Z is a group in which Q represents a 3-membered divalent residue completing a 5-membered a |
| 5212163 |
Compounds |
May 18, 1993 |
| Novel compounds of formula (I) and salts, solvates and hydrates thereof, processes for their preparation and their use in the treatment of conditions in which degradation of connective tissue and other proteinaceous components of the body occurs: ##STR1## in which, R is hydrogen, |
| 5204330 |
Antifungal compounds |
April 20, 1993 |
| A compound of formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## wherein: R.sub.1 is a group --CH.sub.2 --X where X is hydrogen, halogen, --CN, --N.sub.3, --OC(O)R.sub.5, --S(O).sub.n R.sub.5, --SH, --OC(O)NHR.sub.5, --NHCONHR.sub.5 or --NR.sub.6 R.sub.7, where R.sub |
| 5200413 |
Indolyl carboxamides useful treating migraine, cluster headache, trigeminal neuralgia or emesis |
April 6, 1993 |
| Compounds of formula (I) and pharmaceutically acceptable salts thereof: ##STR1## wherein L is NH;X and Y are independently selected from hydrogen or C.sub.1-4 alkyl, or together are a bond;R.sub.1 and R.sub.2 are independently selected from hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkeny |
| 5200179 |
Vaccine |
April 6, 1993 |
| Sterile pharmaceutical compositions for use in therapy especially inactivated vaccines for use in prophylaxis, are prepared by inactivating a live virus or bacterium with ascorbic acid and/or a salt thereof in the presence of oxygen and a source of heavy metal ions. Methods of treating |
| 5194443 |
Compounds |
March 16, 1993 |
| Compounds of formula (I): ##STR1## or a tautomeric form thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, wherein:A.sup.1 represents a substituted or unsubstituted aromatic heterocyclyl group;R.sup.1 represents a hydrogen atom, |
| 5191093 |
Process for preparing crystalline calcium pseudomonate |
March 2, 1993 |
| Processes for the preparation of these salts and their use in human and veterinary medicine and as a growth promoter in animals are described. |
| 5190937 |
Lactam derivatives |
March 2, 1993 |
| Novel compounds of formula (I), and pharmaceutically acceptable salts thereof; their preparation; compositions containing them; and their use in the treatment of conditions in which degradation of connective tissue and other proteinaceous components of the body occurs: ##STR1## i |
| 5175288 |
Process for preparing purine derivatives and intermediates thereof |
December 29, 1992 |
| A process for preparing pharmaceutically active compounds of formula (A): ##STR1## wherein X is hydrogen, hydroxy, chloro, C.sub.1-6 alkoxy or phenyl C.sub.1-6 alkoxy; and R.sub.a and R.sub.b are hydrogen, or acyl or phosphate derivatives thereof, which process comprises the preparat |
| 5166357 |
Compounds |
November 24, 1992 |
| A compound of formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## in which one of X and Y represents hydrogen and the other represents Z, where Z is a group ##STR2## in which Q represents a 3-membered divalent residue completing a 5-membered aromatic ring and |
| 5159076 |
Purine intermediates |
October 27, 1992 |
| Compounds of formula (II): ##STR1## wherein R.sub.4 ' is R.sub.4 whereinR.sub.4 is hydrogen, hydroxy, amino or OR.sub.5 whereinR.sub.5 is C.sub.1-6 alkyl, phenyl or phenyl C.sub.1-2 alkyl either of which phenyl moieties may be substituted by one or two halo, C.sub.1-4 alkyl or C.sub. |
| 5157160 |
Certain 5-substituted-1-azabicyclo[3.1.1]heptanes and their pharmaceutical use |
October 20, 1992 |
| A compound of formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## in which Z is a heterocyclic group ##STR2## in which Q represents a 3-membered divalent residue completing a 5-membered aromatic ring and comprises one or two heteroatoms selected from oxygen, n |
